BioNotebook: ImmunoGen, Seattle Genetics, Keryx, OncoMed

00:51 EST 6 Nov 2013 | SCRIP

ImmunoGen sinks on Phase II ADC failure; Seattle Genetics revenue grows; Keryx rises on Phase II data; and OncoMed earns $15m milestone.

Original Article: BioNotebook: ImmunoGen, Seattle Genetics, Keryx, OncoMed

NEXT ARTICLE

More From BioPortfolio on "BioNotebook: ImmunoGen, Seattle Genetics, Keryx, OncoMed"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Advertisement

Searches Linking to this Story